Skip to main content

Table 1 Clinical characteristics of advanced CCA patients

From: Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment

Characteristics

CCA patients (N = 40)

Age (years), mean ± SD

62.2 ± 9.4

Sex, n (%)

 

 Female

13 (32.5)

 Male

27 (67.5)

ECOG PS score, n (%)

 

 0

4 (10.0)

 1

26 (65.0)

 2

10 (25.0)

Lesion location, n (%)

 

 Intrahepatic

22 (55.0)

 Hilar

14 (35.0)

 Extrahepatic

4 (10.0)

Lymph node metastasis, n (%)

27 (67.5)

Distant metastasis, n (%)

27 (67.5)

TNM stage, n (%)

 

 III

12 (30.0)

 IV

28 (70.0)

Abnormal CA199, n (%)

33 (82.5)

Abnormal CA125, n (%)

25 (62.5)

Abnormal CEA, n (%)

16 (40.0)

Previous surgery, n (%)

9 (22.5)

Previous chemotherapy, n (%)

19 (47.5)

Previous radiotherapy, n (%)

5 (12.5)

  1. CCA: cholangiocarcinoma; SD: standard deviation; ECOG PS: Eastern Cooperative Oncology Group performance status; TNM: tumor-node-metastasis; CA199: cancer antigen 19 − 9; CA125: cancer antigen 125; CEA: carcinoembryonic antigen